The objective. The aim is to present the major effects of cancer treatment (chemotherapy, radiotherapy, surgery) that the anaes thesiologist should consider preoperatively, and to review tech niques of the analgesic management of the disease.
INTRODUCTION
Cancer is a leading health problem worldwide. According to epidemiological data, approximate ly 40% of people have a chance to develop cancer during their lifetime. Chemotherapy, radiother apy, and surgery are techniques for cancer treat ment with different side effects on the human body. To prepare the best preoperative, intraop erative and postoperative management plans for patients with a history of cancer, the knowledge of longterm and acute side effects caused by these methods of treatment is required of anaesthesiol ogists. In addition, anaesthesiologists play a major role in the analgesic management of the disease for patients in severe pain (1) (2) (3) .
A literature review was conducted to summa rize the major challenges that cancer patients pre sent to the anaesthesiologists. Articles which pre sented evidence or reviewed the possible effects of anaesthetics on cancer cells were also included. Keywords such as "current cancer therapies", "can cer anaesthesia", "oncologic anaesthesia", "compli cations of anticancer therapy", "perioperative", "cancer surgery", "propofol cancer", "immunity", etc. were used to search databases. Online data bases of Science Direct, PubMed, and ELSEVIER, as well as reference lists of included studies were searched and articles published from 2005 to 2016 were selected.
CHEMOTHERAPY AND RADIOTHERAPY
Chemotherapy can be neoadjuvant (given before surgery to reduce the tumour size), adjuvant (giv en during or after surgery), and palliative (given to improve the quality of life). A lot of chemotherapy drugs are antiproliferative agents targeting rapid ly dividing cancer cells. However, nonmalignant dividing cells are also affected. Consequently, toxicity of drugs leads to acute and longterm ef fects on the human organism. The most common toxicities include pulmonary, cardiac, renal, he patic, and gastrointestinal systems, bone marrow and neurological damage ( Table 1) . Knowledge of the possible effects of commonly used anticancer drugs is necessary for anaesthesiologists to pre pare patients with a history of cancer for anaes thesia and surgery (4) (5) (6) .
Bleomycin is an anticancer drug used to treat Hodgkin's disease and germ cell tumours. The worst complication of bleomycin therapy is a subacute pulmonary damage that can progress to pulmonary fibrosis. Faster progression of pul monary toxicity is associated with an exposure to oxygen therapy of highinspired concentration (4, 6) . The anthracyclines (epirubicin, doxorubicin) are the drugs implicated in cardiotoxicity. This is the reason why invasive arterial pressure and car diac output monitoring to maintain normal physi ological parameters for patients previously treated with anthracyclines would be necessary (4, 6) .
The platinumbased chemotherapy agents (cis platin, carboplatin, and oxaliplatin) are nephro toxic. They can cause either acute or chronic renal failure. The nephrotoxic process is augmented by dehydration and concurrent use of nonsteroidal antiinflammatory drugs. Careful fluid optimiza tion and dosage of analgesics are imperative peri operatively (6) .
A lot of chemotherapy drugs are metabolized by the liver. Anaesthetic drug dosage must be re duced for patients with an impaired liver function. Regional anesthesia is contraindicated in the cas es of the associated coagulopathy (6) .
Gastrointestinal toxicity is common after the administration of chemotherapy drugs. Side effects, which include nausea, vomiting, mucositis and diarrhoea, lead to dehydration. In these cases, prescription of fluids and electrolytes is indicated before surgery. Rapid sequence induction of an aesthesia should be considered. Furthermore, it should be known that laryngoscopy may exacer bate the mucositis and lead to severe bleeding (6) .
Most chemotherapy drugs affect bone marrow and the peripheral blood cells. It leads to myelo suppression which is usually reversible within six weeks of cessation of chemotherapy. The anaemia as a secondary response of malignant disease is curable without blood transfusion within a peri od of 2-3 weeks. However, transfusion of blood products may be required in the cases of anaemia caused by myelosuppression and urgent surgery. It should be remembered that anaemia treated with preoperative blood transfusion may recur in the postoperative period. This is the reason why patients should be followed up after surgery. Neu tropenia is associated with infections postopera tively. To avoid severe complications, broadspec trum antibiotics must be administered. The use of granulocyte colonystimulating factors for neutropenic patients who are undergoing surgery is controversial. Platelet transfusion must be bal anced against the prothrombotic state that cancer induces for cancer patients with thrombocytope nia. A patient with pancytopenia should be con sulted by a haematologist before surgery (4, 6, 7) .
The most common agents with neurotoxic side effects are vincristine and cisplatin. The vinca alka loid vincristine is used to treat lymphoma, leukae mia, and can cause peripheral neuropathy, muscle pain, cranial neuropathy, and seizures. However, the major problems for anaesthesiologists are as sociated with the effects on the autonomic nerv ous system: the development of orthostatic hypo tension and vocal cord palsy. Preoperatively, a full neurological examination to detect any neurolog ical damage should be conducted (5, 6) .
Chemotherapy drugs are frequently combined in various ways, which causes multiple side ef fects. Furthermore, commonly used drugs contin ued during anaesthesia may inactivate antican cer drugs or lead to an increased risk of bleeding (Table 2) (4, 5, 8) .
Radiotherapy is frequently used in combina tion with chemotherapy. Chemoradiation for oe sophageal, pulmonary, cervical, head and neck, rectal and urinary bladder cancers can be used to achieve a complete antitumour response. Radio therapy causes tissue damage through the produc tion of oxygenfree radicals. As a consequence, they can cause delayed wound healing, induration of the skin, vascular stenosis, myocarditis, pneu monitis, and pulmonary fibrosis. Anaesthesiolo gists are faced with the challenge of management of patients with head and neck cancer. Airway management of these patients is difficult because of the site and size of the tumour. Previous treat ment with radiotherapy could also lead to a limit ed neck extension and rigidity of the oropharyn geal tissues. This makes ventilation with a face mask and laryngoscopy difficult. Radiotherapy for the head and neck leads to a difficult central venous access. Therefore, in the cases of a long term treatment with chemotherapy, a central or peripherally inserted central venous catheter is frequently needed. Furthermore, mucositis as a consequence of radiotherapy can be exacerbated by tracheal intubation (1, 5, 6, 9, 10) .
Chemotherapy and radiotherapy have a broad range of complications and toxicity. Therefore, preoperative assessment to identify any side ef fects of treatment, as well as structured intraop erative and postoperative management plans, is required for all patients with a history of can cer. The interval between the end of neoadjuvant chemotherapy and surgery depends on the type of cancer. A treatment plan aimed at choosing the best interval for surgery to avoid acute side effects of chemotherapy should be discussed with oncologists. For example, myelosupression, coag ulation disorders, renal or hepatic impairment, or anaphylactic reactions may develop unexpectedly.
SURGERY AND ANAESTHETIC TECHNIQUES
Surgery is a method of cancer treatment used frequently. Surgery is also performed for preven tive, diagnostic, staging, debulking, supportive, and palliative purposes. A major cancer surgery has an influence on neuroendocrine (the hypo thalamic-pituitary axis, the sympathetic nervous system) and cytokinemediated stress responses followed by immunosuppression. Furthermore, circulating tumour cells are released and tumour emboli are disseminated during surgery. This is the reason, why surgery itself is suspected to be associated with an increased risk of metastasis and recurrence of cancer. Several studies have suggested that perioperative anaesthetic, anal gesic techniques, and drugs may affect a postop erative inflammation and the immune function (2, 3, 11).
Regional anaesthesia and analgesia may influ ence cancer recurrence. Lidocaine and bupivacaine inhibit transcription pathways associated with the initiation and metastasis of cancer and with decreased mesenchymal stemcell proliferation. The use of regional anaesthesia, especially thoracic epidural analgesia, has a variety of benefits for pa tients postoperatively: improved analgesia as well as reduction of opioidsassociated side effects, in flammatory response and adrenergic response to increased circulating catecholamine levels, factors believed to be mediating postoperative immune suppression. Regional anaesthesia may increase the expression of several cytokines expressed peri operatively, including IL4 and IL10, which may directly or indirectly attenuate the surgeryinduced proinflammatory response and reduce the rate of postoperative complications. Alternatively, local anaesthetics may directly stimulate natural kill er cells (NKcell) activity. NKcells are important in the destruction of tumour cells. Local anaesthet ics are suggested to have antiproliferative and cy totoxic effects on cancer cells (3, 11) .
Volatile agents are associated with immune modulation and potentially increase the ability of tumour metastasis. The possible mechanisms are decrease of NKcell activity, interference with lymphocyte antigen activity, and induction of ap optosis in Tlymphocytes and in Blymphocytes. Furthermore, volatile agents may have direct ef fects on cancer cells (12, 13) .
Nonvolatile agents such as nonvolatile anaes thetic gas nitrous oxide (N 2 O) and the intrave nous anaesthetic agents (ketamine, thiopentone, propofol) are being investigated for their immune modulating effects and potential effects on cancer recurrence. It was determined in the studies that lowdose ketamine suppresses NKcell cytotoxicity and inhibits the production of proinflammatory cytokines (IL6 and TNFa). As a consequence, im mune suppression is associated with the recurrence of cancer. However, propofol may have an antican cer effect. Different studies made in vitro established a lot of mechanisms how propofol acts as an antican cer agent: it inhibits tumour size, cell viability, induc es cell apoptosis, or inhibits invasion and angiogene sis of cancer (14) (15) (16) (17) .
Opioids have different effects on the immune re sponse and the reason is unclear. The pathways of endogenous opioids are thought to induce antican cer effects whereas exogenous opioids are believed to have procancer effects. Endorphin increases NK cells cytotoxicity and favours antiinflammatory cy tokines. Therefore endorphin has been considered as a possible anticancer therapeutic agent. Exogenous opioids suppress the immune function. They inhibit humoral and cellmediated immune functions and increase tumour growth rate (3).
To conclude, general anaesthetics do not cause the development of cancer directly. However, im mune suppression induced by anaesthesia could lead to a faster progress of cancer. On the contra ry, regional anaesthesia and anaesthetic induction with propofol are associated with the prevention or reduction of perioperative immunosuppression. Larger prospective studies to determine the role of anaesthetic techniques for prevention of tumour re currence or metastasising are required (18) (19) (20) .
PHARMACOLOGICAL MANAGEMENT OF CANCER PAIN
Severe cancer pain, which does not seem to be re lieved using the threestep "pain ladder" method (step 1 being employed for the treatment of mild cancer pain with non-opioid analgesia, step 2 for moderate pain with "weak" opioids and step 3 for severe pain with "strong" opioids), is uncommon but can occur in up to 10% of patients. In those pa tients, interventional pain management techniques, including simple local anaesthetic blocks, possibly maintained for a prolonged term by insertion of peripheral nerve catheters, as well as techniques of neuraxial analgesia and, finally, neurodestructive techniques may be considered (21) .
Nerve blocks. Myofascial trigger point infiltra tions may be useful in some patients. Otherwise, peripheral nerve blocks can provide shortterm re lief in acute situations, for example, before surgical repair of a pathological fracture. In the cases of a ter minal situation with pathological fractures, catheters to peripheral neural structures and continuous infu sions of local anaesthetic can provide a management option for days or weeks (22) .
Neuraxial analgesia. The most widely accepted method is the insertion of an intrathecal catheter with continuous administration of opioids, com monly combined with local anesthetics and other adjuvants, particularly clonidine. It is possible to use percutaneous catheters connected to external pumps for weeks and months provided that strict asepsis and excellent care are applied (19) .
Neurodestructive procedures. Neurodestructive procedures can be performed with the use of neuro lytic agents as well as with the application of exces sive temperatures by radiofrequency or cryoneurol ysis. Percutaneous chordotomy is the destruction of the spinothalamic tract, made usually by radio fre quency lesioning. It could be used to treat unilateral pain on the opposite side (23) .
Neurolytic sympathetic blocks. For the treatment of pain originating from upper abdominal cancers the most and best experience is available with coeliac plexus neurolysis, especially in cases of the pancre atic cancer. An alternative technique is the neuroly sis of the splanchnic nerves. Neurolytic procedures to the superior hypogastric plexus or to the lumbar sympathetic chain addressing pain originating from the lower abdomen and the pelvis could be used suc cessfully. Another sympathetic neurolytic block is that of the ganglion impair, the terminal bit of the sympa thetic chain. It is used for the treatment of pain origi nating from the prostatic or rectal cancer (24) .
Terminal sedation. Even at the end of life, pain can usually be controlled with continuation of opioids, using the subcutaneous route if needed. When death is near, these symptoms and/or refractory pain may require to be managed with palliative sedation (21) .
CONCLUSIONS
Currently, cancer is a leading health problem worldwide. To provide the best treatment to cancer patients, cooperation of anaesthesiologists with oncologists and surgeons becomes imperative. It is obvious that radiochemotherapy and surgery are important in the treatment of cancer, and an aesthesiology facilitates their advance. However, treatment techniques may have significant acute and longterm side effects on the human body. Therefore preoperative assessment to identify any side effects from the treatment, structured intra operative and postoperative management plan are required for all patients with a history of cancer. It is established that anaesthetic techniques and drugs could minimize perioperative inflammatory and immune changes. Apparently, this could lead to better outcomes for cancer patients in the fu ture. However, further research into perioperative "oncoanesthetic" and perioperative cancer med icine is needed.
